Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Merck & Co., Inc.
MRK
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $309.8B
$129.52
▲ +3.31%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$76.66 - $130.29
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 52.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Diversified pharmaceutical portfolio across high-demand therapeutic areas with strong pipeline
- Established brand reputation and 130+ years of healthcare innovation and trust
- Dual revenue streams from human and animal health markets reducing sector concentration risk
- Strategic partnerships with leading biotech and pharmaceutical companies accelerating drug development
- Extensive distribution network reaching wholesalers, hospitals, government agencies, and institutional clients
Bear Case
2 risks
- Low volatility (beta 0.2).
- Significant premium - growth priced in
Growth
Stable outlook
Rising global demand for oncology and immunology treatments as cancer incidence increases
Value
Significant premium - growth priced in
Momentum
Stable
+3.8% over 3m
Quality
Excellent
Excellent business quality
Dividend
Solid
2.68% yield
Smart-money signal
Who's buying MRK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 23, 2026
APR 30, 2026
Reported EPS of -$1.28 vs -$1.47 consensus (+12.9% surprise). Revenue of $16.3B vs $15.8B expected (+2.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+12.9%
Next: Apr 23, 2026
Revenue trend · last 8Q
—
—
+7%
-2%
-2%
+4%
+4%
+5%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$16.1B
$16.7B
$15.6B
$15.5B
$15.8B
$17.2B
$16.3B
$16.3B
Margins · last 8Q
Gross
81.9%
Operating
-11.6%
Profit
-26.0%
Wall Street consensus
12 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
$140.00
▲ +8.1% vs $129.52
Latest: Citi · Jun 30, 2026
3 analysts covering